| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Controversies on the Consequences of Iron Overload and Chelation in MDS |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
|
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
|
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
| Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation |
|
Haematologica |
Aplastic Anemia |
| Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation |
|
Haematologica |
Aplastic Anemia |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
